Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reloxaliase in secondary hyperoxaluria and kidney stones
NCT02547805Phase 2Completed
- Sponsor
- Allena Pharmaceuticals, Inc.
- Start
- Sep 2015
- Primary completion
- Jan 2017
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in secondary hyperoxaluria and nephrolithiasis comparing Placebo with ALLN-177 (2 arms). Primary endpoint: Mean change in urinary oxalate excretion at 28 days. Started Sep 2015; status: completed.
02
Drugs
reloxaliase
03
Conditions
secondary hyperoxalurianephrolithiasis
Beyond the preview
Go deeper on NCT02547805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02547805.